Jan Benes1, Martin Kotrc1, Peter Wohlfahrt2, Michael J Conrad3, Janka Franekova4, Antonin Jabor4, Petr Lupinek1, Josef Kautzner1, Vojtech Melenovsky1, Petr Jarolim5. 1. Department of Cardiology, Institute for Clinical and Experimental Medicine-IKEM, Prague, Czech Republic. 2. Department of Cardiology, Institute for Clinical and Experimental Medicine-IKEM, Prague, Czech Republic; Center for Cardiovascular Prevention of the First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic. 3. Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. 4. Department of Laboratory Methods, Institute for Clinical and Experimental Medicine-IKEM, Prague, Czech Republic; Third Faculty of Medicine, Charles University, Prague, Czech Republic. 5. Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. Electronic address: pjarolim@bwh.harvard.edu.
Abstract
BACKGROUND: Growth differentiation factor-15 (GDF-15) is a stress-inducible cytokine and member of the transforming growth factor-β cytokine superfamily that refines prognostic assessment in subgroups of patients with heart failure (HF). We evaluated its role in HF patients with chronic kidney disease (CKD, estimated glomerular filtration rate <60 mL/min/1.73 m2). METHODS: A total of 358 patients with stable systolic HF were followed for a median of 1121 (interquartile range, 379-2600) days. Comprehensive evaluation including B-type natriuretic peptide (BNP) and GDF-15 testing was performed at study entry; the analysis was stratified according to kidney function. RESULTS: Patients with CKD (33.8%) were older, had more often diabetes, and were less often treated with angiotensin converting enzyme inhibitors (ACEi)/angiotensin receptor blockers (ARB). GDF-15 was associated with estimated glomerular filtration rate, whereas BNP was associated with left ventricular-end diastolic diameter and ejection fraction (P < 0.01). During follow-up, 244 patients (68.2%) experienced an adverse outcome (death, urgent transplantation, implantation of mechanical circulatory support). In patients with HF and CKD, the Cox proportional hazard model identified BNP, GDF-15, sex, systolic blood pressure, sodium, total cholesterol, and ACEi/ARB treatment as significant variables associated with an adverse outcome (P < 0.05). In multivariable analysis, BNP was replaced by GDF-15. Net reclassification improvement confirmed prognostic superiority of the model encompassing GDF-15 (GDF-15, sodium, total cholesterol, ACEi/ARB treatment) compared with the model without GDF-15 (BNP, sex, sodium, ACEi/ARB treatment), net reclassification improvement 0.62, P = 0.005. In contrast, in patients with HF and normal kidney function, BNP remained superior to GDF-15 in a multivariable model. CONCLUSIONS: In patients with systolic HF and CKD, GDF-15 is more strongly associated with adverse outcomes than the conventionally used BNP.
BACKGROUND:Growth differentiation factor-15 (GDF-15) is a stress-inducible cytokine and member of the transforming growth factor-β cytokine superfamily that refines prognostic assessment in subgroups of patients with heart failure (HF). We evaluated its role in HF patients with chronic kidney disease (CKD, estimated glomerular filtration rate <60 mL/min/1.73 m2). METHODS: A total of 358 patients with stable systolic HF were followed for a median of 1121 (interquartile range, 379-2600) days. Comprehensive evaluation including B-type natriuretic peptide (BNP) and GDF-15 testing was performed at study entry; the analysis was stratified according to kidney function. RESULTS:Patients with CKD (33.8%) were older, had more often diabetes, and were less often treated with angiotensin converting enzyme inhibitors (ACEi)/angiotensin receptor blockers (ARB). GDF-15 was associated with estimated glomerular filtration rate, whereas BNP was associated with left ventricular-end diastolic diameter and ejection fraction (P < 0.01). During follow-up, 244 patients (68.2%) experienced an adverse outcome (death, urgent transplantation, implantation of mechanical circulatory support). In patients with HF and CKD, the Cox proportional hazard model identified BNP, GDF-15, sex, systolic blood pressure, sodium, total cholesterol, and ACEi/ARB treatment as significant variables associated with an adverse outcome (P < 0.05). In multivariable analysis, BNP was replaced by GDF-15. Net reclassification improvement confirmed prognostic superiority of the model encompassing GDF-15 (GDF-15, sodium, total cholesterol, ACEi/ARB treatment) compared with the model without GDF-15 (BNP, sex, sodium, ACEi/ARB treatment), net reclassification improvement 0.62, P = 0.005. In contrast, in patients with HF and normal kidney function, BNP remained superior to GDF-15 in a multivariable model. CONCLUSIONS: In patients with systolic HF and CKD, GDF-15 is more strongly associated with adverse outcomes than the conventionally used BNP.
Authors: Susana Rocha; Maria João Valente; Susana Coimbra; Cristina Catarino; Petronila Rocha-Pereira; José Gerardo Oliveira; José Madureira; João Carlos Fernandes; Maria do Sameiro-Faria; Vasco Miranda; Luís Belo; Alice Santos-Silva; Elsa Bronze-da-Rocha Journal: Sci Rep Date: 2021-07-20 Impact factor: 4.379
Authors: Marina de Cos Gomez; Adalberto Benito Hernandez; Maria Teresa Garcia Unzueta; Jaime Mazon Ruiz; Covadonga Lopez Del Moral Cuesta; Jose Luis Perez Canga; David San Segundo Arribas; Rosalia Valero San Cecilio; Juan Carlos Ruiz San Millan; Emilio Rodrigo Calabia Journal: J Clin Med Date: 2020-12-20 Impact factor: 4.241
Authors: Jan Benes; Martin Kotrc; Katerina Kroupova; Peter Wohlfahrt; Jan Kovar; Janka Franekova; Marketa Hegarova; Lenka Hoskova; Eva Hoskova; Terezie Pelikanova; Petr Jarolim; Josef Kautzner; Vojtech Melenovsky Journal: Sci Rep Date: 2022-07-29 Impact factor: 4.996